Valuation: Daxor Corporation

Market Cap 58.41M 51.21M 47.21M 44.2M 82.87M 5.51B 84.59M 567M 220M 2.72B 219M 215M 9.44B P/E 2026 *
-47.7x
P/E 2027 * -334x
Enterprise Value 58.41M 51.21M 47.21M 44.2M 82.87M 5.51B 84.59M 567M 220M 2.72B 219M 215M 9.44B EV / Sales 2026 *
4.91x
EV / Sales 2027 * 2.81x
Free-Float
47.22%
Yield 2026 *
-
Yield 2027 * -
1 day-1.71%
1 week+5.85%
Current month+0.39%
1 month+4.51%
3 months+1.78%
6 months-25.81%
Current year-30.03%
1 week 9.52
Extreme 9.52
10.65
1 month 9.26
Extreme 9.26
11.16
Current year 8.56
Extreme 8.56
14.75
1 year 8.56
Extreme 8.56
14.76
3 years 6.55
Extreme 6.55
14.76
5 years 6.55
Extreme 6.55
14.76
10 years 3.4
Extreme 3.4001
24.08
Manager TitleAgeSince
Chief Executive Officer 56 2012-12-31
Director of Finance/CFO 69 2018-09-27
Chief Tech/Sci/R&D Officer - 2024-06-04
Director TitleAgeSince
Director/Board Member 91 1988-12-31
Chairman 56 2017-02-13
Director/Board Member 70 2016-06-21
Date Insider Type Main position Quantity % Market Cap.
06-22Free

Chief Technology Officer

25,000 0.4290%
06-22Free

Director

2,500 0.0429%
06-22Free

Director

2,500 0.0429%
Change 5-day change 1-year change 3-year change Capi.($)
-1.71%+5.85%+12.79%+7.50% 58.41M
+1.19%-3.65%+22.59%+106.88% 14.62B
+1.91%-10.86%+54.07%+140.93% 11.91B
-0.42%-2.84%-3.93%+34.40% 8.78B
+0.61%+1.41%-12.19%-11.34% 7.65B
+1.53%-6.65%+35.51%+125.13% 7.47B
+0.15%-2.68%+2.11%+55.41% 6.34B
-0.26%+1.48%+8.48%+24.79% 4.6B
+0.18%+1.96%+11.11%+6.03% 4.11B
-0.46%-7.14% - - 3.7B
Average +0.27%-2.45%+14.51%+54.41% 6.92B
Weighted average by Cap. +0.74%-4.12%+18.47%+74.49%

Financials

2026 *2027 *
Net sales 11.9M 10.43M 9.62M 9M 16.88M 1.12B 17.23M 116M 44.73M 555M 44.68M 43.71M 1.92B 20.8M 18.24M 16.81M 15.74M 29.51M 1.96B 30.12M 202M 78.18M 970M 78.1M 76.4M 3.36B
Net income -1.2M -1.05M -970K -908K -1.7M -113M -1.74M -11.66M -4.51M -55.95M -4.51M -4.41M -194M -200K -175K -162K -151K -284K -18.87M -290K -1.94M -752K -9.32M -751K -735K -32.33M
Net Debt - -
Logo Daxor Corporation
Daxor Corporation is a diversified, closed-end management investment company. Its focus and operations are as a medical device manufacturing, company. It specializes in blood volume measurement technology focused on blood volume testing innovation. It markets the Blood Volume Analyzer (BVA)-100, the diagnostic blood test cleared by the FDA to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000 tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. Its facility provides on-demand, next day blood volume analysis results. It has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the United States Department of Defense.
Employees
45
Date Price Change Volume
26-06-26 US$10.02 -2.87% 1,854
26-06-25 US$10.32 -1.71% 550
26-06-24 US$10.50 +3.50% 8,411
26-06-23 US$10.14 +6.79% 2,812
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
10.02USD
Average target price
22.50USD
Spread / Average Target
+124.47%

Quarterly revenue - Rate of surprise